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Background: The aim of this study was to compare the long-term survival outcome and late 
toxicity in patients with FIGO (International Federation of Gynecology and Obstetrics) stage IIB 
cervical carcinoma after two treatment modalities, ie, concurrent chemoradiotherapy followed 
by radical surgery and concurrent chemoradiotherapy followed by high-dose-rate intracavitary 
brachytherapy.
Methods: Between November 2004 and November 2011, 240 patients with FIGO stage IIB 
cervical carcinoma were analyzed, comprising 119 patients treated with concurrent chemo-
radiotherapy followed by radical surgery (group 1) and 121 patients treated with concurrent 
chemoradiotherapy followed by high-dose-rate intracavitary brachytherapy (group 2). Local 
control, overall survival, progression-free survival, and treatment-related complications were 
compared between the two groups.
Results: The median follow-up duration was 36 months. Concurrent chemoradiotherapy fol-
lowed by radical surgery showed a survival benefit when comparing group 1 and group 2 (3-year 
overall survival, 94.9% versus 84.6%, P=0.011; 3-year progression-free survival, 91.0% versus 
81.8%, P=0.049, respectively). Three-year local pelvic control was 94.6% in group 1 and 93.3% 
in group 2 (P=0.325). Prognostic factors in group 1 were: age (#35 years versus .35 years), 
3-year progression-free survival (74.1% versus 90.9%, P=0.037); tumor diameter ($6 cm versus 
,6 cm); and 3-year progression-free survival, (60.6% versus 92.9%, P=0.004). Prognostic factors 
in group 2 were: tumor diameter ($4 cm versus ,4 cm); 3-year overall survival (78.0% versus 
94.8%, P=0.043); tumor diameter ($6 cm versus ,6 cm); 3-year progression-free survival 
(42.9% versus 84.2%, P=0.032); and 3-year overall survival (42.9% versus 87.1%, P=0.013). 
Further, 50 patients (42.02%) in group 1 and 46 patients (38.02%) in group 2 suffered from 
late complications. Analysis of the difference in composition of late complications showed that 
the rate of leg edema was higher in group 1 (35.29% versus 4.96%, P=0.000) while the rate of 
radiation enteritis was higher in group 2 (30.58% versus 5.04%, P=0.000).
Conclusion: In patients with FIGO stage IIB cervical carcinoma, concurrent chemoradiotherapy 
followed by radical surgery achieved higher overall survival and progression-free survival rates in 
comparison with radical radiotherapy associated with concurrent chemotherapy. Tumor diameter 
could be a common prognostic factor in these two groups of patients.
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Introduction
Concurrent cisplatin-based chemoradiotherapy is the stan-
dard treatment for locally advanced cervical carcinoma 
(LACC) based on five clinical trials (GOG85, Radiation 
Therapy Oncology Group [RTOG] 9001, GOG123, GOG120, 
SWOG 8797) and two meta-analyses.1,2 However, the 5-year 
survival of patients with LACC is still around 70%.3 In the 
GOG123 trial, survival status after concurrent chemoradio-
therapy followed by radical surgery was better than after 
radiotherapy alone in patients with FIGO (International 
Federation of Gynecology and Obstetrics) stage IB2 cervical 
carcinoma, but for FIGO stage IIB, the large-scale interna-
tional clinical experimental experience concerning surgical 
benefit is rare, especially in contrast with radical radiotherapy. 
Neoadjuvant treatments followed by radical surgery have 
been proposed, with data for overall survival and disease-free 
survival reported as ranging from 57% to 85% and from 64% 
to 90%, respectively.4,5 More recently, there have been reports 
that adjuvant surgery after chemoradiotherapy may represent 
a more effective strategy by removing radiochemoresistant 
foci,6–8 so it is still necessary to investigate the surgical benefits 
in patients with LACC.
About 80% of new cervical carcinoma cases are diag-
nosed in developing countries,9 and although 72% of patients 
with FIGO stage IIB cervical carcinoma are treated with 
definitive radiotherapy according to the annual FIGO report, 
in most high-risk areas of Asia, the majority of these patients 
undergo radical hysterectomy. For example, 62.7% of such 
patients have been reported to receive surgery-based therapy 
in Japan.10–12 It is becoming increasingly important to com-
pare the benefit of surgery in patients with FIGO stage IIB 
cervical carcinoma, especially in high-risk Southeast Asia, 
with the disease reduction achieved in European countries 
and in the US.
In this paper, we report the results of a comparison 
between concurrent chemoradiotherapy followed by radi-
cal surgery and concurrent chemoradiotherapy followed by 
high-dose-rate intracavitary brachytherapy in 240 patients 
with FIGO stage IIB cervical carcinoma in high-risk regions 
of the People’s Republic of China. Long-term survival and 
late toxicity were observed, and some prognostic factors are 
identified.
Materials and methods
selection criteria
From November 2004 to November 2011, 240 patients 
with FIGO stage IIB cervical carcinoma were treated at the 
Department of Radiation Oncology, Xijing Hospital, Fourth 
Military Medical University, People’s Republic of China. 
All patients had a Karnofsky performance status $70 
and had no history of other malignancy or treatment for 
carcinoma. Pretreatment evaluations comprised the patient’s 
medical history, a blood count, liver and renal function tests, 
a gynecologic examination, cervical biopsy, chest X-ray, 
transvaginal ultrasound, abdominal ultrasonography, and 
pelvic magnetic resonance imaging (MRI). Tumor sizes 
were basically determined by MRI imaging. Patients had 
to have adequate bone marrow, hepatic, and renal function 
with the following criteria: a leukocyte count $3,000/mm3, 
a platelet count $100,000/mm3, hemoglobin $10 g/dL, total 
bilirubin #1.5 mg/dL, aspartate aminotransferase/alanine 
aminotransferase no more than twice the upper limit of 
normal, and serum creatinine #1.5 mg/dL.
Treatment modalities
concurrent chemoradiotherapy
Pelvic external beam radiotherapy (EBRT) was delivered 
using three-dimensional conformal radiation techniques and 
6 mV or 15 mV photons using a linear accelerator, ie, a Varian 
23EX (Varian Medical Systems, Palo Alto, CA, USA) or a 
600 C/D (Varian Medical Systems). Patients were immobi-
lized on a custom vacuum mattress in the supine position and 
underwent a computed tomography simulation scan using a 
PQS and an AcQSim (Philips Health Care, Andover, MA, 
USA) with intravenous contrast and a 5 mm slice thickness. 
The clinical target volume included the gross tumor, cervix, 
uterus, parametrium, upper part of the vagina to 3 cm below 
the tumor invasion (according to the T2 MRI image), and 
regional lymph nodes (common, external, internal iliac, obtu-
rator, and presacral). Positive lymph nodes were delineated as 
having a minimum diameter $1 cm, being necrotic, or involv-
ing multiple lymph nodes. The planning target volume was 
defined by uniform three-dimensional expansion around the 
clinical target volume, using 7 mm margins around the lymph 
nodes, 10 mm around the vagina and parametrium, and 15 mm 
around the cervix and gross disease. Treatment was designed 
and computed using the PLATO system version 2.7.5. The 
EBRT dose was 40–50 Gy in 20–25 fractions. Radiotherapy 
was withheld when hematologic toxicity reached grade 4 or 
nonhematologic toxicity reached grade 3–4. Radiotherapy 
was resumed when hematologic and nonhematologic toxicity 
recovered to grade 2.
Concurrent chemotherapy was administered in 4–6 cycles 
by an intravenous infusion of weekly cisplatin (40 mg/m²) 
during pelvic EBRT. Chemotherapy was withheld under the 
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absolute neutrophil count ,1.0 × 109/L, platelet count 
,50 × 109/L, or grade 3–4 radiation enteritis or cystitis.
All 240 patients had a good response to standard treat-
ment, with a decrease in tumor volume of at least 50% accord-
ing to MRI on completion of concurrent chemoradiotherapy. 
The patients were divided into two groups, ie, for radical 
surgery or for high-dose-rate intracavitary brachytherapy. The 
choice of therapeutic modality depended mainly on patient 
preference, except in those who could not undergo surgery 
because of severe cardiac or pulmonary disease. Three such 
patients received intracavitary brachytherapy because of 
comorbidity, comprising two with a history of arrhythmia 
and one older patient (aged 71 years) with a permanent 
cardiac pacemaker.
concurrent chemoradiotherapy followed  
by radical surgery (group 1)
Group 1 patients (n=119) underwent radical abdominal hys-
terectomy and pelvic lymphadenectomy. The interval between 
preoperative concurrent chemoradiotherapy and radical sur-
gery was 2–3 weeks. The resected primary and lymph node 
specimens were processed into sections for hematoxylin and 
eosin staining and pathologic observation. The pathologic 
response to neoadjuvant therapy was evaluated based on 
histopathologic examination of the resected specimens, ie, 
uterus, vaginal cuff, parametrium, and pelvic lymph nodes.
radical radiotherapy associated with concurrent 
chemotherapy (group 2)
Group 2 patients (n=121) underwent radical radiotherapy. 
The whole pelvic EBRT dose was boosted to 50 Gy in 
25 fractions, and positive lymph nodes were boosted 
to 64–66 Gy. Computed tomography-based image-guided 
brachytherapy was applied at the conclusion of pelvic EBRT, 
and concurrently with boost radiation to the lymph nodes. 
An Ir-192 source was used for high-dose-rate intracavitary 
brachytherapy. high-dose-rate intracavitary brachytherapy 
was delivered with 28–35 Gy in 4–5 fractions to 90% of 
the high-risk clinical target volume (D90), using interstitial 
implantation or an intracavity applicator (microSelectron-
HDR Ir-192 set or Fletcher applicator set, Nucletron, 
Veenendaal, The Netherlands). The treatment procedure for 
patients in group 1 and group 2 is shown schematically in 
Figure 1.
Follow-up
Patients were followed up at 3-monthly intervals in the first 
year and at 6-monthly intervals thereafter with regular gyne-
cologic examination, laboratory studies (blood count, liver 
and renal function tests), transvaginal ultrasound, abdominal 
ultrasonography, superficial lymph node examination, and 
radiographic studies, including chest computed tomography 
and/or pelvic MRI.
Toxicity assessment was performed according to the 
RTOG/European Organization for Research and Treatment for 
Carcinoma late radiation morbidity scoring scheme.13 Surgical 
complications were classified using the Chassagne grading 
system.14,15 Overall survival and progression-free survival 
rates were calculated from the date of surgery or completion 
of intracavitary brachytherapy to the last follow-up date.
statistical analysis
Statistical analysis was performed using Statistical Pack-
age for the Social Sciences version 17 software (SPSS Inc, 
Group 1
(n=119)
Group 2
(n=121)
EBRT 40–50 Gy/20–25 f
After 2–3 weeks
Radical
surgery
HDR-ICBT EBRT  50 GY/25 f
Associated with
lymph node boost to
64–66 Gy
Associated with weekly
cisplatin (40 mg/m2),
4–6 cycle
Associated with weekly
cisplatin (40 mg/m2),
4–6 cycle
Follow up
Figure 1 schematic diagram showing treatment procedure for 240 patients in group 1 and group 2.
Abbreviations: eBrT, external beam radiotherapy; hDr-icBT, high-dose-rate intracavitary brachytherapy.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Chicago, IL, USA). Overall survival and progression-free 
survival rates were computed by the Kaplan–Meier method 
and are shown. Differences in the survival curves were 
estimated using the log-rank test. Multivariate analysis was 
performed by linear logistic regression. Other estimations 
were performed using the chi-square test. P-values less than 
0.05 were considered to be statistically significant.
Results
Patient characteristics
The median follow-up is 36 (range 2–75) months. There are 
118 patients with a follow-up period of more than 3 years 
(61 patients in group 1 and 57 patients in group 2). The 
median age is 45 (range 25–71) years. One hundred and 
nineteen patients received concurrent chemoradiotherapy fol-
lowed by radical surgery in group 1, and 121 patients received 
radical radiotherapy with concurrent chemotherapy (weekly 
cisplatin 40 mg/m2) in group 2. Of note, none of the patients in 
group 1 accepted postoperative adjuvant therapy. An overall 
treatment time of more than 56 days has been correlated with 
a bad prognosis. All patients in group 1 completed their full 
treatment in 56 days. However, in group 2, overall treatment 
time ranged from 45 to 99 days, with a median of 60 days. 
No patient had an extension of overall treatment time because 
of severe toxicity. The main reason for extension of overall 
treatment time in group 2 was socioeconomic problems. 
Patient characteristics are shown in Table 1.
survival outcomes
Concurrent chemoradiotherapy followed by radical surgery 
in group 1 showed a survival benefit compared with group 2 
(3-year overall survival 94.9% versus 84.6%, P=0.011; 3-year 
progression-free survival 91.0% versus 81.8%, P=0.049) 
(Figure 2). Three-year local pelvic control was 94.6% in 
group 1 and 93.3% in group 2, respectively (P=0.325).
In group 1, local regional failure developed in five 
patients (4.20%). Distant metastasis developed in seven 
patients (5.88%). One patient developed pelvic recurrence 
and liver metastasis concurrently. One patient in group 1 
developed postoperative intestinal obstruction. In group 2, 
local regional failure developed in eight patients (6.61%) 
and distant metastasis developed in 13 patients (10.74%). 
Of note, one patient died from a second primary tumor 
(leukemia) in group 2. Distant metastasis was still the 
main reason for treatment failure in these two groups. No 
patients died from non-tumor-related diseases or reasons. 
Table 1 Patient characteristics
Characteristics Group 1 (n=119) Group 2 (n=121) χ2 P-value
Patients, n (%) Patients, n (%)
Median age (range, years) 
  .35 
  #35
45, 27–65 
110 (92.44%) 
9 (7.56%)
52, 25–71 
117 (96.69%) 
4 (3.31%)
 
2.122
 
0.165
KPs score
  90 46 (38.66%) 42 (34.71%) 0.402 0.592
  80 66 (55.46%) 73 (60.33%) 0.583 0.513
  70 7 (5.88%) 6 (4.96%) 0.100 0.783
Tumor diameter (cm) 
(range, median, mean)
1.2–8.0, 4.5, 4.43 1.5–6.5, 4.0, 3.88
  $4 cm 93 (78.15%) 74 (61.16%) 8.187 0.005**
  ,4 cm 26 (21.85%) 47 (38.84%)
  $6 cm 11 (9.24%) 7 (5.79%) 1.034 0.337
  ,6 cm 108 (90.76%) 114 (94.21%)
Pathologic types
  scc 112 (94.12%) 116 (95.87%) 0.387 0.569
  non-scc 7 (5.88%) 5 (4.13%)
ln involvement
  + 13 (10.92%) 24 (19.83%) 3.653 0.073
  − 106 (89.08%) 97 (80.17%)
eBrT dose 
  40–45 gy 
  46–50 gy
 
39 
80
 
28 
93
 
2.766
 
0.114
Median follow-up 
(range, months)
36, 7–75 30, 2–70 0.173
Abbreviations: eBrT, external beam radiotherapy; KPs, Karnofsky performance status; scc, squamous cell carcinoma; ln, lymph node. ** P,0.01.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Table 2  Treatment  failure  patterns  in  group  1  and  group  2 
patients
Group 1  
(n=119)
Group 2  
(n=121)
χ2 P-value
Patients,  
n (%)
Patients,  
n (%)
Pelvic recurrence 5 (4.20%) 8 (6.61%) 0.680 0.570
Total distant  
metastasis
7 (5.88%) 13 (10.74%) 1.856 0.243
  lung metastasis 3 (2.52%) 6 (4.96%)
  Bone metastasis 1 (0.84%) 4 (3.31%)
    lymph node  
metastasis
2 (1.68%) 4 (3.31%)
  liver metastasis 1 (0.84%) 0
second primary  
tumor
0 1 (0.83%) 0.988 1.000
Total treatment  
failure
11* (9.24%) 22# (18.18%) 4.042 0.060
Notes: no patient has died for non-tumor-related reasons. *One case suffered 
from pelvic recurrence and liver metastasis concurrently in group 1;  #One case 
suffered from bone metastasis and lymph node metastasis concurrently in group 2.
Table 3 correlations between clinical/pathologic factors and survival outcome in group 1
Prognostic  
factors
Patients,  
n
3-year  
OS
P-value Exp (B)  
HR
95% CI 3-year  
PFS
P-value Exp (B)  
HR
95% CI
Lower Upper Lower Upper
age
 # 35 years 9 88.9% 0.258 0.278 0.030 2.552 74.1% 0.037* 0.167 0.031 0.894
 . 35 years 110 95.4% 90.9%
Primary tumor
 , 4 cm 26 96.2% 0.797 1.353 0.135 13.562 96.0% 0.653 1.468 0.275 7.844
 $ 4 cm 93 94.6% 87.8%
Primary tumor
 , 6 cm 108 96.3% 0.122 0.232 0.038 1.405 92.9% 0.004** 0.140 0.036 0.542
 $ 6 cm 11 81.8% 60.6%
eBrT dose
  40–45 gy 39 87.5% 0.961 0.000 0.000 3.030 87.1% 0.432 0.415 0.046 3.725
  46–50 gy 80 96.6% 93.3%
ln involvement
  + 13 92.3% 0.145 0.296 0.057 1.524 80.8% 0.422 0.536 0.117 2.455
  − 106 95.2% 90.4%
Abbreviations: CI, confidence interval; HR, hazard ratio; SCC, squamous cell carcinoma; EBRT, external beam radiotherapy; LN, lymph node; OS, overall survival; PFS, 
progression-free survival * P,0.05; ** P,0.01.
Treatment failure patterns in the two groups are summarized 
in Table 2.
Tumor size as a key prognostic factor
Prognostic factors in group 1 were: age (#35 years 
versus .35 years); 3-year progression-free survival (71.4% ver-
sus 90.9%, P=0.037); tumor diameter ($6 cm versus ,6 cm); 
and 3-year progression-free survival (60.6% versus 92.9%, 
P=0.004). Prognostic factors in group 2 were: tumor diameter 
($4 cm versus ,4 cm); 3-year overall survival (78.0% versus 
94.8%, P=0.043); tumor diameter ($6 cm versus ,6 cm); 
3-year progression-free survival (42.9% versus 84.2%, 
P=0.032); and 3-year overall survival (42.9% versus 87.1%, 
P=0.013). These data are shown in Tables 3, 4 and Figure 3.
Postoperative pathologic  
response in group 1
Pathologic responses to neoadjuvant therapy were further 
evaluated in group 1 based on histopathologic examination. 
The postoperative pathologic response included complete 
response, partial response, and residual carcinoma.   Complete 
response was defined as complete disappearance of all 
macroscopic and microscopic disease; partial response as 
presence of persistent atypical cells or cervical intraepithelial 
neoplasia; and residual carcinoma as macroscopic and/or 
microscopic residual disease. The complete response rate 
was 27.73% (33/119), the partial response rate was 41.18% 
(49/119), and the residual carcinoma rate was 31.09% 
(37/119). The total effective pathologic alleviation rate was 
68.91%, including complete responses (33/119, 27.73%) and 
partial responses (49/119, 41.18%).
late toxicity
Fifty patients (50/119, 42.02%) in group 1 and 46 patients 
(46/121, 38.02%) in group 2 suffered late complications 
(Table 5). Of note, 12 patients in group 1 suffered from at 
least two types of complications concurrently, and eight 
patients in group 2 suffered from at least two types of com-
plications concurrently. There was no statistically significant 
difference in total late complication rate between the two OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Figure 2 Overall survival and progression-free survival in group 1 and group 2 patients, respectively. Patients in group 1 show a survival benefit in comparison with those 
in group 2. Three-year overall survival in group 1 was 94.9% and in group 2 was 84.6% (*P=0.011). Three-year progression-free survival in group 1 was 91.0% and in group 2 
was 81.8% (* P=0.049).
Abbreviations: Os, overall survival; PFs, progression-free survival; ccrT, concurrent chemoradiotherapy; icBT, intracavitary brachytherapy.
groups, but the composition showed obvious differences. 
The rate of leg edema in group 1 was higher than in group 2 
(35.29% versus 4.96%, P=0.000), and the radiation enteritis 
rate in group 2 was higher than in group 1 (30.58% versus 
5.04%, P=0.000). The data indicate that radiation enteritis 
was more common in group 2 and might be correlated with 
intracavitary brachytherapy and boost radiation to the lymph 
nodes. The median number of lymph node dissections was 
18 (range 6–42) in group 1, and after subgroup analysis, the 
data showed that leg edema occurred more frequently when 
pelvic lymph node dissection was $20 (55.56% versus 
29.79%, P=0.022).
Discussion
The treatment strategy used for LACC has changed over 
the past two decades. Combined treatment modalities have 
Table 4 correlations between clinical/pathologic factors and survival outcome in group 2
Prognostic  
factors
Patients, n 3-year  
OS
P-value Exp (B)  
HR
95% CI 3-year  
PFS
P-value Exp (B)  
HR
95% CI
Lower Upper Lower Upper
age
  #35 years 4 75.0% 0.590 1.849 0.198 17.265 75.0% 0.619 1.745 0.195 15.648
  .35 years 117 84.9% 82.0%
Primary tumor
  ,4 cm 47 94.8% 0.043* 0.211 0.047 0.949 89.4% 0.127 0.444 0.157 1.258
  $4 cm 74 78.0% 77.0%
Primary tumor
  ,6 cm 114 87.1% 0.013* 0.179 0.046 0.700 84.2% 0.032* 0.226 0.058 0.882
  $6 cm 7 42.9% 42.9%
OTT
  $56 days 44 83.1% 0.347 0.602 0.201 1.732 79.2% 0.202 0.523 0.193 1.416
  ,56 days 77 86.4% 86.2%
ln involvement
  + 24 86.4% 0.700 1.276 0.369 4.409 80.3% 0.431 1.632 0.483 5.515
  − 97 87.5% 84.2%
Abbreviations: CI, confidence interval; HR, hazard ratio; SCC, squamous cell carcinoma; OTT, overall treatment time; LN, lymph node; OS, overall survival; OTT, overall 
treatment time; PFs, progression-free survival * P,0.05.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Figure 3 Overall survival and progression-free survival are shown regarding tumor size as a prognostic factor with a boundary of 6 cm in group 1 (A and B) (3-year overall 
survival, P=0.122; 3-year progression-free survival, P=0.004) and with a boundary of 4 cm in group 2 (C and D) (3-year overall survival, P=0.043; 3-year progression-free 
survival, P=0.127).
Abbreviations: Os, overall survival; PFs, progression-free survival.
Table 5 late complications in group 1 and group 2 patients
Late  
complications
Group 1  
(n=119)
Group 2  
(n=121)
χ2 P-value
Patients,  
n (%)
Patients,  
n (%)
irradiation enteritis 
  grade 1 
  grade 2
6 (5.04%) 
6 
0
37 (30.58%) 
23 
14
26.603 0.000**
irradiation cystitis 
  grade 1 
  grade 2
10 (8.40%) 
10 
–
10 (8.26%) 
7 
3
0.002 1.000
leg edema 
  grade 1 
  grade 2
42 (35.29%) 
32 
10
6 (4.96%) 
4 
2
34.507 0.000**
Uronephrosis 5 (4.20%) 1 (0.83%) 2.804 0.118
Thrombus 3 (2.52%) 0 3.089 0.120
intestinal  
obstruction
1 (0.84%) 0 1.021 0.496
Note: ** P,0.01.
focused on radical radiotherapy associated with concurrent 
chemotherapy, preoperative concurrent chemoradiotherapy 
with completion surgery, and neoadjuvant chemotherapy fol-
lowed by completion surgery in recent years.16–20   According to 
the FIGO annual report of 2003, 72% of patients with FIGO 
stage IIB cervical carcinoma were treated with definitive 
  radiotherapy.12 In contrast, surgery is preferentially utilized 
over radiotherapy in most high-risk Southeast Asian areas, so 
it is still important to explore the surgical benefit for LACC 
patients. In this retrospective study, we used patients who 
underwent radical radiotherapy associated with concurrent 
chemotherapy as the historical concurrent control group. 
Concurrent chemoradiotherapy followed by radical surgery 
showed a survival benefit in patients with FIGO stage IIB 
cervical carcinoma.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Both radical radiotherapy and surgery can destroy malig-
nant cervical and paracervical cells as well as regional lymph 
nodes. However, surgery is recommended in several reports 
because it can remove chemoradiotherapy-resistant foci.7,21,22 
For example, Houvenaeghel et al22 reported on 30 patients 
with advanced cervical carcinoma and bulky residual disease 
($2 cm) after concurrent chemoradiotherapy who accepted 
curative surgery. In the absence of para-aortic involve-
ment, 80% of these patients were still alive 5 years after 
curative surgery. This result suggests that adjuvant surgery 
might improve the outcome of patients with bulky residual 
disease after concurrent chemoradiotherapy. Lèguevaque 
et al18 reported that additional surgery after concurrent 
chemoradiotherapy followed by brachytherapy improved 
disease-free survival by reducing pelvic recurrence. In their 
study, disease-free survival and overall survival were com-
pared in 111 patients with FIGO stage IB1 to IVA disease 
(mainly FIGO stage IIB [55/111, 49.5%]). The recurrence 
rate was lower in patients who underwent completion 
surgery with less than 50% residual tumor than in patients 
with a good response to concurrent chemoradiotherapy 
who were therefore treated conservatively (22.4% versus 
36.4%, P=0.01). This research suggests that surgery could 
have a survival benefit for patients who do not have a good 
response to concurrent chemoradiotherapy by removing 
chemoradiotherapy-resistant foci.
Pelvic recurrence and distant metastasis could be decreased 
as a consequence of removal of chemoradiotherapy-  resistant 
foci. Carcopino et al23 reported on the survival outcome in 
patients with FIGO stage IB–IVA cervical carcinoma who 
underwent surgery after concurrent chemoradiotherapy. 
Surgery was curative in 127 cases and pelvic control was 
achieved in 114 cases. Pelvic control and survival rates were 
equivalent in patients with stage IB–II and III–IVA disease, 
suggesting that adjuvant surgery following chemoradio-
therapy may improve local control, enabling patients with 
stage III–IVA disease to have a survival outcome comparable 
with that of patients with stage IB–II disease. In our study, 
surgical-based treatment (group 1) also achieved better 
pelvic control and an improved survival outcome, and this 
result is consistent with the other published research. For 
example, Kato et al24 reported a multi-institutional Phase II 
clinical study from East and Southeast Asia in which 120 
patients with LACC (60 with bulky stage IIB disease) 
accepted concurrent chemoradiotherapy using five cycles 
of weekly cisplatin. Radiotherapy consisted of pelvic EBRT 
(total dose 50 Gy) and intracavitary brachytherapy. This 
treatment modality was similar to that used for group 2 in 
our study. In that Phase II clinical study, the 2-year pelvic 
tumor control rate for patients with bulky stage IIB disease 
was 94.2%. In our study, the 2-year pelvic tumor control rate 
in group 2 (93.3%) was comparable with that in the report 
by Kato et al (94.2%).
Distant metastasis is still the main reason for treatment 
failure. Recent research suggests that local pelvic failure is 
associated with a higher risk of metastasis. In our study, dis-
tant metastasis occurred more frequently in group 2 (13/121, 
10.74%) than in group 1 (7/119, 5.88%). We therefore 
deduced that radical surgery could decrease the risk of metas-
tasis by clearing the pelvic lymph nodes, and could also bring 
about a survival benefit by removal of radiochemotherapy-
resistant foci, thereby improving pelvic control in patients 
with FIGO stage IIB cervical carcinoma.
Size of the primary tumor is an independent risk factor 
for local regional failure and survival according to mul-
tivariate analysis.25 In a previous study, we showed that 
preoperative concurrent chemoradiotherapy can improve 
progression-free survival and overall survival compared 
with radiotherapy alone when the tumor diameter is less 
than 5 cm, indicating that the beneficial effect of concur-
rent chemotherapy might be limited or depend on tumor 
size.26 In the present work, the size of the primary tumor 
was still an independent risk factor in group 1 patients with 
a boundary of 6 cm and those in group 2 with a boundary of 
4 cm. The mean tumor diameter in group 1 (4.43 cm) was 
larger than that in group 2 (3.88 cm), and the difference in 
tumor size between these two groups was statistically sig-
nificant for a boundary of 4 cm (P=0.005), but the survival 
outcome was better in group 1. This result implies that 
surgical treatment could alleviate the adverse prognostic 
effect of primary tumor burden. Based on this difference, 
we deduced that radical surgery could bring about a survival 
benefit for patients with a bulky tumor burden by removing 
radiochemotherapy-resistant foci, which is consistent with 
other published research,18 but this conclusion needs to be 
validated in a large number of patients.
The use of a three-modality treatment can achieve survival 
outcomes compared with those achieved by exclusive use 
of chemoradiotherapy. However, one of the concerns about 
surgery following chemoradiotherapy is surgical morbidity. 
Tummers et al21 reported on the outcome of surgery after 
chemoradiotherapy (with intensity-modulated arc therapy) 
in 34 patients with LACC, and their complication rates 
are comparable with those of primary surgery for cervical 
carcinoma. In our study, the main complication in group 1 
was leg edema, and the number of lymph node dissections OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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($20) is related to the risk of leg edema. Further study 
should focus on how to decrease the rate of lymph node 
metastasis, with a view to determining the feasibility and 
safety of individualized surgical treatment. We do believe 
that a new concept of radical surgery based on intraoperative 
findings might decrease the risk of surgical complications.27 
The main complication in group 2 was radiation enteritis 
(30.58% versus 5.04%, P=0.000). The patient distribution 
between group 1 and group 2 with regard to EBRT dose 
was not significantly different (Table 1, P=0.114), so it was 
deduced that the higher rate of radiation enteritis in group 2 
might be related to intracavitary brachytherapy and boost 
radiation to the lymph nodes. Of 24 patients in group 2 who 
accepted boost radiation to the lymph nodes, seven (29.2%) 
developed enteritis.
Overall treatment time is potentially a poor prognostic 
factor, with a boundary of 56 days for cervical carcinoma. 
All patients in group 1 received their full treatment in 
56 days, with longer treatment courses occurring mainly 
in group 2 (median 60 days; range 45–99 days). According 
to research reported by Huang et al, tumor repopulation 
is indeed a problem.28 Accelerated tumor repopulation has 
significant implications in low-dose-rate brachytherapy, 
and dose escalation may be required to compensate for 
the effects of tumor repopulation if the course of radia-
tion therapy is protracted. In our study, patients in group 2 
accepted high-dose-rate but not low-dose-rate intracavitary 
brachytherapy after EBRT. On the other hand, EBRT dose 
compensation (0.6 Gy/day) was given to patients with a 
long EBRT treatment course.
The survival outcome did not show a statistically sig-
nificant difference with regard to overall treatment time 
($56 days versus ,56 days) in group 2. Considering the 
fact that the median follow-up has been relatively short 
(36 months), we shall continue our observations to validate 
this conclusion by extension of follow-up.
In conclusion, this study has shown that concurrent 
chemoradiotherapy followed by radical surgery could lead to 
a better survival outcome in comparison with that achieved 
by radical radiotherapy with weekly cisplatin in 240 patients 
with FIGO stage IIB cervical carcinoma. Late complications 
were acceptable and comparable between the two treatment 
groups. Tumor diameter might also represent a prognostic 
factor for these patients. In view of the weakness of any 
conclusion based on a single institution and retrospective 
experience, we plan to perform a randomized multicenter 
prospective study in a greater population of subjects to vali-
date our conclusion.
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